Physician profile
Catherine E Vanarsdall
NPI 1922770221
$866.62
in general payments reported to CMS, 2019-2025
13 companies · $867 in 2025
The $867 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $867.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $866.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $360.69 | 2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $103.48 | 2025 | |
| Novo Nordisk INC | $80.62 | 2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $69.08 | 2025 | |
| Lilly USA, LLC | $55.11 | 2025 | Kisunla, Jardiance |
| Exact Sciences Corporation | $50.87 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $34.90 | 2025 | Trelegy Ellipta |
| Amgen INC. | $32.77 | 2025 | Repatha, Otezla |
| Astellas Pharma US INC | $17.18 | 2025 | Veozah |
| Dynavax Technologies Corporation | $16.30 | 2025 | Heplisav-B |
| Cipher Pharmaceuticals US LLC | $16.30 | 2025 | Natroba, Spinosad |
| Esperion Therapeutics, INC. | $14.67 | 2025 | Nexletol |
| Kowa Pharmaceuticals America, INC. | $14.65 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Vanarsdall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.